SINGAPORE: A new drug to treat advanced stage prostate cancer may prolong lives and mitigate pain for patients whose conditions have worsened while on, or after chemotherapy.
Called Zytiga, the pill has been approved by the Health Sciences Authority of Singapore.
Prostate cancer is the third most common cancer among Singaporean men.
In global clinical trials, patients lived an average of 4.6 months longer after taking the drug.
One professor sent me this note: Increasing life span by 4.6 months using zytiga (abiraterone acetate) with accompanying side effects is said to be an achievement. It is ridiculous to any good academic.